Literature DB >> 22446096

Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients.

A Bisgin1, A D Yalcin, R M Gorczynski.   

Abstract

We examined the association between serum sTRAIL measured by ELISA and HbA1C levels, pre/post-prandial blood glucose levels and body mass index in 22 newly diagnosed type-2 diabetic patients. A significant difference in sTRAIL levels was found between study group and controls.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22446096     DOI： 10.1016/j.diabres.2012.02.028

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  14 in total

Review 1.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

2.  Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.

Authors:  Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Parlak; Atil Bısgın
Journal:  Med Sci Monit       Date:  2012-10

Review 3.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261

4.  Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Authors:  Siân P Cartland; Hanis H Harith; Scott W Genner; Lei Dang; Victoria C Cogger; Melissa Vellozzi; Belinda A Di Bartolo; Shane R Thomas; Leon A Adams; Mary M Kavurma
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

5.  HDL Improves Cholesterol and Glucose Homeostasis and Reduces Atherosclerosis in Diabetes-Associated Atherosclerosis.

Authors:  Belinda A Di Bartolo; Siân P Cartland; Scott Genner; Pradeep Manuneedhi Cholan; Melissa Vellozzi; Kerry-Anne Rye; Mary M Kavurma
Journal:  J Diabetes Res       Date:  2021-05-06       Impact factor: 4.011

6.  Correlation between Polymorphism of TRAIL Gene and Condition of Intervertebral Disc Degeneration.

Authors:  Shimin Xu; Ting Liang; Shuzhong Li
Journal:  Med Sci Monit       Date:  2015-08-06

7.  Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers.

Authors:  Hasan Onur Arık; Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Genç; Adil Turan; Ahter Dilsad Sanlioglu
Journal:  Med Sci Monit       Date:  2013-08-29

8.  Evaluation of soluble CD200 levels in type 2 diabetic foot and nephropathic patients: association with disease activity.

Authors:  Hasan Onur Arik; Arzu Didem Yalcin; Betul Celik; Derya Seyman; Gulsum Tetik; Bensu Gursoy; Sukran Kose; Saadet Gumuslu
Journal:  Med Sci Monit       Date:  2014-06-26

9.  Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.

Authors:  Wen Cheng; Fangfang Liu; Zhe Wang; Yun Zhang; Yu-Xia Zhao; Qunye Zhang; Fan Jiang
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

10.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms.

Authors:  Belinda Ann Di Bartolo; Siân Peta Cartland; Leonel Prado-Lourenco; Thomas Scott Griffith; Carmine Gentile; Jayant Ravindran; Nor Saadah Muhammad Azahri; Thuan Thai; Amanda Wing Shee Yeung; Shane Ross Thomas; Mary Meltem Kavurma
Journal:  J Am Heart Assoc       Date:  2015-11-16       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.